IDEXX Laboratories stock heads into the open after a modest pullback
Published on 09/18/2026 at 04:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories stock closed on Nasdaq on September 17, 2026 with a modest decline from its recent levels, following a strong run earlier in the year. The move came as broader technology and growth shares saw mixed trading and the Nasdaq Composite finished virtually unchanged for the session.
September 17, 2026 in numbers
IDEXX Laboratories Inc. (ISIN US45168D1046, Nasdaq: IDXX) entered September 17, 2026 after a stretch of gains that left the shares up more than the S&P 500 year to date, with recent data indicating a market capitalization near USD 40 billion. Per Nasdaq data from a major financial portal, the stock was quoted intraday around USD 504.51 on September 17, 2026, down 1.77 percent at 10:46 a.m. Eastern Time compared with its previous close of approximately USD 513.62 on September 16, 2026, with the price movement consistent with a typical day range for the shares. In the same period, trailing total returns as of September 17, 2026 showed IDEXX ahead of the S&P 500, with the shares up about 25.43 percent year to date versus an 11.39 percent rise in the index, underscoring the stock's stronger performance profile in recent months.
As Business Wire reported on September 17, 2026, IDEXX announced the expansion of its Faecal Dx antigen testing platform in the United Kingdom with Taeniid tapeworm detection, adding to its parasite diagnostics menu for veterinary practices. On the same day, a French-language release from Business Wire detailed similar expansion of Fecal Dx antigen testing in France, reinforcing the company's focus on zoonotic parasite detection. Commentary from Zacks on September 17, 2026 highlighted earlier gains in IDEXX stock following the acquisition of CoVetAI, a move seen as strengthening its capabilities in veterinary diagnostics and related software solutions. Against this backdrop of product expansion and acquisition-driven strategy, the Nasdaq Composite closed virtually flat on September 17, 2026, sliding just 3.15 points to finish at 25,978.43, according to a market wrap from Zacks, indicating that IDEXX's pullback occurred in a largely steady index environment.
Today’s factors for IDEXX Laboratories stock
Today, September 18, 2026, IDEXX Laboratories stock approaches the open without a scheduled earnings release or major corporate event appearing in recent calendars, and the shares reflect a balance between strong year-to-date performance and short-term consolidation. The latest product announcements in tapeworm and zoonosis testing in the United Kingdom and France remain in focus for investors assessing how expanded diagnostic offerings could support future revenue growth and sustain the stock's premium relative to broader healthcare benchmarks, as highlighted by coverage from Yahoo Finance on September 17, 2026. With the Nasdaq Composite having ended the last session almost unchanged, macro sentiment around technology and growth names may continue to shape appetite for IDEXX shares today alongside ongoing evaluation of its diagnostic pipeline and acquisition strategy.
